Top

Current Breast Cancer Reports

Published in:

01-12-2018 | Systemic Therapies (M Liu and T Haddad, Section Editors)

Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer

Authors: Evanthia T. Roussos Torres, Roisin M. Connolly

Published in: Current Breast Cancer Reports | Issue 4/2018

Abstract

Purpose of Review

HER2-positive early breast cancer has been revolutionized by the development of HER2-directed therapy, which has significantly reduced breast cancer recurrence risk and improved overall survival. Here, we review the available treatment options for this patient population and discuss how we might individualize therapy in the future to optimize the balance of efficacy and toxicity.

Recent Findings

The addition of pertuzumab to a trastuzumab-based adjuvant regimen improves pathologic complete response rates and invasive disease-free survival (DFS). Addition of neratinib for patients with high-risk disease also contributes to improved DFS.

Summary

Current data supports use of dual HER2-directed therapy in combination with chemotherapy, as well as extended HER2-directed therapy (beyond 1 year), in those with high-risk HER2-positive early breast cancer. Ongoing studies aim to identify biomarkers of response and resistance to standard approaches, as well as identify those who might benefit from a chemotherapy-free treatment paradigm.

Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987 Jan 9 [cited 2018 Jun 25];235(4785):177–82. Available from: http://www.ncbi.nlm.nih.gov/pubmed/3798106.CrossRef

Arteaga CL, Engelman JA. ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell. 2014 Mar 17 [cited 2018 Jun 25];25(3):282–303. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24651011.CrossRef

Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug 17 [cited 2018 Jun 25];406(6797):747–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/10963602.CrossRef

Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989 May 12 [cited 2018 Jun 25];244(4905):707–12. Available from: http://www.ncbi.nlm.nih.gov/pubmed/2470152.CrossRef

Ménard S, Pupa SM, Campiglio M, Tagliabue E. Biologic and therapeutic role of HER2 in cancer. Oncogene. Nature Publishing Group; 2003 Sep 3 [cited 2018 Jun 25];22(42):6570–8. Available from: http://www.nature.com/articles/1206779 CrossRef

Lemmon MA, Schlessinger J, Ferguson KM. The EGFR family: not so prototypical receptor tyrosine kinases. Cold Spring Harb Perspect Biol. Cold Spring Harbor Laboratory Press; 2014 Apr 1 [cited 2018 Jun 25];6(4):a020768. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24691965.

Hynes NE, Lane HA. ERBB receptors and cancer: the complexity of targeted inhibitors. Nat Rev Cancer. 2005 May [cited 2018 Jun 25];5(5):341–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15864276.CrossRef

• Wolff AC, Hammond MEH, Allison KH, Harvey BE, McShane LM, Dowsett M. HER2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update Summary. J Oncol Pract. American Society of Clinical Oncology; 2018 Jun 19 [cited 2018 Jun 25];JOP1800206. Available from: https://doi.org/10.1200/JOP.18.00206. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline. CrossRef

Slamon DJ, Leyland-Jones B, Shak S, Fuchs H, Paton V, Bajamonde A, et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med. 2001 Mar 15 [cited 2018 Jun 25];344(11):783–92. Available from: http://www.nejm.org/doi/abs/10.1056/NEJM200103153441101 CrossRef

10.

Perez EA, Romond EH, Suman VJ, Jeong J-H, Davidson NE, Geyer CE, et al. Four-year follow-up of trastuzumab plus adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol [Internet]. 2011 Sep 1 [cited 2018 Jun 25];29(25):3366–73. Available from: http://ascopubs.org/doi/10.1200/JCO.2011.35.0868 CrossRef

11.

Perez EA, Suman VJ, Davidson NE, Gralow JR, Kaufman PA, Visscher DW, et al. Sequential versus concurrent trastuzumab in adjuvant chemotherapy for breast cancer. J Clin Oncol. 2011 Dec 1 [cited 2018 Jun 25];29(34):4491–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22042958.CrossRef

12.

Gianni L, Dafni U, Gelber RD, Azambuja E, Muehlbauer S, Goldhirsch A, et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol. 2011 Mar [cited 2018 Jun 25];12(3):236–44. Available from: http://linkinghub.elsevier.com/retrieve/pii/S147020451170033X CrossRef

13.

Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, et al. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. Massachusetts Medical Society; 2011 Oct 6 [cited 2018 Jun 25];365(14):1273–83. Available from: http://www.nejm.org/doi/10.1056/NEJMoa0910383 CrossRef

14.

•• von Minckwitz G, Procter M, de Azambuja E, Zardavas D, Benyunes M, Viale G, et al. Adjuvant pertuzumab and trastuzumab in early HER2-positive breast cancer. N Engl J Med. 2017 Jul 13 [cited 2018 Aug 6];377(2):122–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28581356. This APHINITY trial provides evidence that pertuzumab significantly improved the rates of invasive-disease–free survival among patients with HER2-positive, operable breast cancer when it was added to trastuzumab and chemotherapy. CrossRef

15.

•• Chan A, Delaloge S, Holmes FA, Moy B, Iwata H, Harvey VJ, et al. Neratinib after trastuzumab-based adjuvant therapy in patients with HER2-positive breast cancer (ExteNET): a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol. Elsevier; 2016 Mar 1 [cited 2018 Aug 6];17(3):367–77. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1470204515005513. This report from the ExteNET trial provides the initial evidence that neratinib for 12 months significantly improved 2-year invasive disease-free survival when given after chemotherapy and trastuzumab-based adjuvant therapy.

16.

• Martin M, Holmes FA, Ejlertsen B, Delaloge S, Moy B, Iwata H, et al. Neratinib after trastuzumab-based adjuvant therapy in HER2-positive breast cancer (ExteNET): 5-year analysis of a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol [Internet]. 2017 Dec [cited 2018 Aug 6];18(12):1688–700. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29146401. 5 year follow-up of the ExteNET trial maintained the recommendation that 1 year of extended adjuvant therapy with neratinib, administered after chemotherapy and trastuzumab, significantly reduced the proportion of clinically relevant breast cancer relapses.

17.

Ahmed S, Sami A, Xiang J. HER2-directed therapy: current treatment options for HER2-positive breast cancer. [cited 2018 Jun 25]; Available from: https://link-springer-com.ezp.welch.jhmi.edu/content/pdf/10.1007%2Fs12282-015-0587-x.pdf.

18.

Cuello M, Ettenberg SA, Clark AS, Keane MM, Posner RH, Nau MM, et al. Down-regulation of the erbB-2 receptor by trastuzumab (herceptin) enhances tumor necrosis factor-related apoptosis-inducing ligand-mediated apoptosis in breast and ovarian cancer cell lines that overexpress erbB-2. Cancer Res. 2001 Jun 15 [cited 2018 Jun 25];61(12):4892–900. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11406568.

19.

Molina MA, Codony-Servat J, Albanell J, Rojo F, Arribas J, Baselga J. Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. Cancer Res. 2001 Jun 15 [cited 2018 Jun 25];61(12):4744–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/11406546.

20.

Junttila TT, Akita RW, Parsons K, Fields C, Lewis Phillips GD, Friedman LS, et al. Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. Cancer Cell. 2009 May 5 [cited 2018 Jun 25];15(5):429–40. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1535610809001093

21.

Arnould L, Gelly M, Penault-Llorca F, Benoit L, Bonnetain F, Migeon C, et al. Trastuzumab-based treatment of HER2-positive breast cancer: an antibody-dependent cellular cytotoxicity mechanism? Br J Cancer. 2006 Jan 30 [cited 2018 Jun 25];94(2):259–67. Available from: http://www.nature.com/articles/6602930 CrossRef

22.

Moja L, Tagliabue L, Balduzzi S, Parmelli E, Pistotti V, Guarneri V, et al. Trastuzumab containing regimens for early breast cancer. Cochrane Database Syst Rev. 2012 Apr 18 [cited 2018 Jun 25];(4):CD006243. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22513938.

23.

McAndrew N, DeMichele A. Neoadjuvant chemotherapy considerations in triple-negative breast cancer. J Target Ther Cancer. NIH Public Access; 2018 Feb [cited 2018 Aug 17];7(1):52–69. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29577076.

24.

Untch M, Rezai M, Loibl S, Fasching PA, Huober J, Tesch H, et al. Neoadjuvant treatment with trastuzumab in HER2-positive breast cancer: results from the GeparQuattro study. J Clin Oncol. 2010 Apr 20 [cited 2018 Aug 20];28(12):2024–31. Available from: http://www.ncbi.nlm.nih.gov/pubmed/20308670.CrossRef

25.

Buzdar AU, Ibrahim NK, Francis D, Booser DJ, Thomas ES, Theriault RL, et al. Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer. J Clin Oncol. 2005 Jun 1 [cited 2018 Aug 20];23(16):3676–85. Available from: http://ascopubs.org/doi/10.1200/JCO.2005.07.032 CrossRef

26.

Cortazar P, Zhang L, Untch M, Mehta K, Costantino JP, Wolmark N, et al. Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis. Lancet. 2014 Jul 12 [cited 2018 Sep 7];384(9938):164–72. Available from: http://www.ncbi.nlm.nih.gov/pubmed/24529560.CrossRef

27.

Gianni L, Eiermann W, Semiglazov V, Lluch A, Tjulandin S, Zambetti M, et al. Neoadjuvant and adjuvant trastuzumab in patients with HER2-positive locally advanced breast cancer (NOAH): follow-up of a randomised controlled superiority trial with a parallel HER2-negative cohort. Lancet Oncol. 2014 May [cited 2018 Aug 9];15(6):640–7. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1470204514700804 CrossRef

28.

Nahta R, Hung M-C, Esteva FJ. The HER-2-targeting antibodies trastuzumab and pertuzumab synergistically inhibit the survival of breast cancer cells. Cancer Res. 2004 Apr 1 [cited 2018 Aug 20];64(7):2343–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/15059883.CrossRef

29.

Scheuer W, Friess T, Burtscher H, Bossenmaier B, Endl J, Hasmann M. Strongly enhanced antitumor activity of trastuzumab and pertuzumab combination treatment on HER2-positive human xenograft tumor models. Cancer Res. 2009 Dec 15 [cited 2018 Aug 20];69(24):9330–6. Available from: http://cancerres.aacrjournals.org/cgi/doi/10.1158/0008-5472.CAN-08-4597 CrossRef

30.

Sergina N V, Rausch M, Wang D, Blair J, Hann B, Shokat KM, et al. Escape from HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3. Nature. 2007 Jan 25 [cited 2018 Aug 20];445(7126):437–41. Available from: http://www.nature.com/articles/nature05474

31.

Nagata Y, Lan K-H, Zhou X, Tan M, Esteva FJ, Sahin AA, et al. PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell. 2004 Aug [cited 2018 Aug 20];6(2):117–27. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1535610804002107 CrossRef

32.

Berns K, Horlings HM, Hennessy BT, Madiredjo M, Hijmans EM, Beelen K, et al. A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell. 2007 Oct [cited 2018 Aug 20];12(4):395–402. Available from: http://linkinghub.elsevier.com/retrieve/pii/S1535610807002620 CrossRef

33.

Baselga J, Cortés J, Kim S-B, Im S-A, Hegg R, Im Y-H, et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med. 2012 Jan 12 [cited 2018 Aug 6];366(2):109–19. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22149875.CrossRef

34.

Gianni L, Pienkowski T, Im Y-H, Roman L, Tseng L-M, Liu M-C, et al. Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol. 2012 Jan [cited 2018 Aug 6];13(1):25–32. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22153890.CrossRef

35.

Schneeweiss A, Chia S, Hickish T, Harvey V, Eniu A, Hegg R, et al. Pertuzumab plus trastuzumab in combination with standard neoadjuvant anthracycline-containing and anthracycline-free chemotherapy regimens in patients with HER2-positive early breast cancer: a randomized phase II cardiac safety study (TRYPHAENA). Ann Oncol. 2013 Sep [cited 2018 Aug 6];24(9):2278–84. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23704196.CrossRef

36.

Yu AF, Singh JC, Wang R, Liu JE, Eaton A, Oeffinger KC, et al. Cardiac safety of dual anti-HER2 therapy in the neoadjuvant setting for treatment of HER2-positive breast cancer. Oncologist. 2017 Jun [cited 2018 Aug 9];22(6):642–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28341761.

37.

Rahmani H, Shahriary A, Sheikhi MA, Ebadi A, Davoodzadeh H. Applications of cardiotoxicity in breast cancer: a meta-analysis. Panminerva Med. 2017 Mar [cited 2018 Aug 9];59(1):90–6. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27314979.

38.

van Ramshorst MS, van Werkhoven E, Honkoop AH, Dezentjé VO, Oving IM, Mandjes IA, et al. Toxicity of dual HER2-blockade with pertuzumab added to anthracycline versus non-anthracycline containing chemotherapy as neoadjuvant treatment in HER2-positive breast cancer: The TRAIN-2 study. The Breast. 2016 Oct [cited 2018 Aug 20];29:153–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/27498129.

39.

Arpino G, Wiechmann L, Osborne CK, Schiff R. Crosstalk between the estrogen receptor and the HER tyrosine kinase receptor family: molecular mechanism and clinical implications for endocrine therapy resistance. Endocr Rev. 2008 Apr [cited 2018 Aug 20];29(2):217–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/18216219.CrossRef

40.

Segovia-Mendoza M, González-González ME, Barrera D, Díaz L, García-Becerra R. Efficacy and mechanism of action of the tyrosine kinase inhibitors gefitinib, lapatinib and neratinib in the treatment of HER2-positive breast cancer: preclinical and clinical evidence. Vol. 5, Am J Cancer Res. 2015 [cited 2018 Aug 6]. Available from: www.ajcr.us/

41.

de Azambuja E, Holmes AP, Piccart-Gebhart M, Holmes E, Di Cosimo S, Swaby RF, et al. Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): survival outcomes of a randomised, open-label, multicentre, phase 3 trial and their association with pathological complete response. Lancet Oncol [Internet]. Elsevier; 2014 Sep 1 [cited 2018 Sep 7];15(10):1137–46. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25130998.

42.

• Piccart-Gebhart M, Holmes E, Baselga J, de Azambuja E, Dueck AC, Viale G, et al. Adjuvant lapatinib and trastuzumab for early human epidermal growth factor receptor 2–positive breast cancer: results from the randomized phase III adjuvant lapatinib and/or trastuzumab treatment optimization trial. J Clin Oncol. 2016 Apr 1 [cited 2018 Aug 6];34(10):1034–42. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26598744. The ALLTO trial provides evidence that adjuvant treatment that includes lapatinib did not significantly improve DFS compared with traztuzumab alone, and added toxicity.

43.

Ballantyne A, Dhillon S. Trastuzumab emtansine: first global approval. Drugs. 2013 May 26 [cited 2018 Aug 9];73(7):755–65. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23620199.CrossRef

44.

Uppal H, Doudement E, Mahapatra K, Darbonne WC, Bumbaca D, Shen B-Q, et al. Potential mechanisms for thrombocytopenia development with trastuzumab emtansine (T-DM1). Clin Cancer Res. 2015 Jan 1 [cited 2018 Oct 9];21(1):123–33. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25370470.CrossRef

45.

• Hurvitz SA, Martin M, Symmans WF, Jung KH, Huang C-S, Thompson AM, et al. Neoadjuvant trastuzumab, pertuzumab, and chemotherapy versus trastuzumab emtansine plus pertuzumab in patients with HER2-positive breast cancer (KRISTINE): a randomised, open-label, multicentre, phase 3 trial. Lancet Oncol. 2018 Jan [cited 2018 Aug 13];19(1):115–26. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29175149. The KRISTINE trial provides evidence that neoadjuvant systemic chemotherapy plus dual HER2-targeted blockade resulted in significantly more patients achieving a pCR than HER2-targeted chemotherapy plus HER2-targeted blockade. CrossRef

46.

A study of trastuzumab emtansine versus trastuzumab as adjuvant therapy in patients with HER2-positive breast cancer who have residual tumor in the breast or axillary lymph nodes following preoperative therapy (KATHERINE) - full text view - ClinicalTrials.gov. [cited 2018 Aug 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT01772472

47.

A study of trastuzumab emtansine (Kadcyla) plus pertuzumab (Perjeta) following anthracyclines in comparison with trastuzumab (Herceptin) plus pertuzumab and a taxane following anthracyclines as adjuvant therapy in participants with operable HER2-positive. [cited 2018 Aug 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT01966471

48.

T-DM1 vs Paclitaxel/Trastuzumab for Breast (ATEMPT Trial) - Full Text View - ClinicalTrials.gov. [cited 2018 Aug 9]. Available from: https://clinicaltrials.gov/ct2/show/NCT01853748

49.

Litière S, Werutsky G, Fentiman IS, Rutgers E, Christiaens M-R, Van Limbergen E, et al. Breast conserving therapy versus mastectomy for stage I-II breast cancer: 20 year follow-up of the EORTC 10801 phase 3 randomised trial. Lancet Oncol [Internet]. Elsevier; 2012 Apr 1 [cited 2018 Aug 23];13(4):412–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/22373563.CrossRef

50.

Swanick CW, Lei X, Shaitelman SF, Schlembach PJ, Bloom ES, Fingeret MC, et al. Longitudinal analysis of patient-reported outcomes and cosmesis in a randomized trial of conventionally fractionated versus hypofractionated whole-breast irradiation. Cancer. Wiley-Blackwell; 2016 Sep 15 [cited 2018 Aug 23];122(18):2886–94. Available from: http://doi.wiley.com/10.1002/cncr.30121

51.

Prat A, Pascual T, Adamo B. Intrinsic molecular subtypes of HER2+ breast cancer. Oncotarget [Internet]. Impact Journals, LLC; 2017 Sep 26 [cited 2018 Aug 9];8(43):73362–3. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29088709.

52.

Dieci M V, Prat A, Tagliafico E, Paré L, Ficarra G, Bisagni G, et al. Integrated evaluation of PAM50 subtypes and immune modulation of pCR in HER2-positive breast cancer patients treated with chemotherapy and HER2-targeted agents in the CherLOB trial. Ann Oncol Off J Eur Soc Med Oncol. 2016 Oct [cited 2018 Aug 9];27(10):1867–73. Available from: https://academic.oup.com/annonc/article-lookup/doi/10.1093/annonc/mdw262 CrossRef

53.

Fumagalli D, Venet D, Ignatiadis M, Azim HA, Maetens M, Rothé F, et al. RNA sequencing to predict response to neoadjuvant anti-HER2 Therapy: a secondary analysis of the NeoALTTO randomized clinical trial. JAMA Oncol [Internet]. 2016 Sep 29 [cited 2018 Aug 9];3(2):227. Available from: http://oncology.jamanetwork.com/article.aspx?doi=10.1001/jamaoncol.2016.3824 CrossRef

54.

Carey LA, Berry DA, Cirrincione CT, Barry WT, Pitcher BN, Harris LN, et al. Molecular Heterogeneity and Response to neoadjuvant human epidermal growth factor receptor 2 targeting in CALGB 40601, a randomized phase III trial of paclitaxel plus trastuzumab with or without lapatinib. J Clin Oncol. 2016 Feb 20 [cited 2018 Aug 9];34(6):542–9. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26527775.CrossRef

55.

Prat A, Bianchini G, Thomas M, Belousov A, Cheang MCU, Koehler A, et al. Research-based PAM50 subtype predictor identifies higher responses and improved survival outcomes in HER2-positive breast cancer in the NOAH study. Clin Cancer Res. 2014 Jan 15 [cited 2018 Aug 9];20(2):511–21. Available from: http://clincancerres.aacrjournals.org/cgi/doi/10.1158/1078-0432.CCR-13-0239 CrossRef

56.

Pogue-Geile KL, Kim C, Jeong J-H, Tanaka N, Bandos H, Gavin PG, et al. Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst. 2013 Dec 4 [cited 2018 Aug 23];105(23):1782–8. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djt321 CrossRef

57.

Salgado R, Denkert C, Demaria S, Sirtaine N, Klauschen F, Pruneri G, et al. The evaluation of tumor-infiltrating lymphocytes (TILs) in breast cancer: recommendations by an International TILs Working Group 2014. Ann Oncol. 2015 Feb [cited 2017 Dec 18];26(2):259–71. Available from: http://www.ncbi.nlm.nih.gov/pubmed/25214542.CrossRef

58.

Perez EA, Thompson EA, Ballman K V, Anderson SK, Asmann YW, Kalari KR, et al. Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol. 2015 Mar 1 [cited 2018 Aug 23];33(7):701–8. Available from: http://ascopubs.org/doi/10.1200/JCO.2014.57.6298 CrossRef

59.

Bianchini G, Pusztai L, Pienkowski T, Im Y-H, Bianchi G V., Tseng L-M, et al. Immune modulation of pathologic complete response after neoadjuvant HER2-directed therapies in the NeoSphere trial. Ann Oncol [Internet]. 2015 Sep 19 [cited 2018 Sep 11];26(12):mdv395. Available from: http://www.ncbi.nlm.nih.gov/pubmed/26387142.

60.

Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al. Single-cell map of diverse immune phenotypes in the breast tumor microenvironment. Cell. Elsevier; 2018 Aug 23 [cited 2018 Sep 7];174(5):1293–1308.e36. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29961579.

61.

Savas P, Virassamy B, Ye C, Salim A, Mintoff CP, Caramia F, et al. Single-cell profiling of breast cancer T cells reveals a tissue-resident memory subset associated with improved prognosis. Nat Med. Nature Publishing Group; 2018 Jul 25 [cited 2018 Sep 7];24(7):986–93. Available from: http://www.nature.com/articles/s41591-018-0078-7 CrossRef

62.

Purmonen TT, Pänkäläinen E, Turunen JHO, Asseburg C, Martikainen JA. Short-course adjuvant trastuzumab therapy in early stage breast cancer in Finland: cost-effectiveness and value of information analysis based on the 5-year follow-up results of the FinHer Trial. Acta Oncol (Madr). 2011 Apr 8 [cited 2018 Aug 9];50(3):344–52. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21299447.CrossRef

63.

Joensuu H, Kellokumpu-Lehtinen P-L, Bono P, Alanko T, Kataja V, Asola R, et al. Adjuvant Docetaxel or vinorelbine with or without trastuzumab for breast cancer. N Engl J Med. Massachusetts Medical Society ; 2006 Feb 23 [cited 2018 Aug 9];354(8):809–20. Available from: http://www.nejm.org/doi/abs/10.1056/NEJMoa053028 CrossRef

64.

Joensuu H, Fraser J, Wildiers H, Huovinen R, Auvinen P, Utriainen M, et al. Effect of adjuvant trastuzumab for a duration of 9 weeks vs 1 year with concomitant chemotherapy for early human epidermal growth factor receptor 2–positive breast cancer. JAMA Oncol. 2018 May 31 [cited 2018 Aug 9]; Available from: http://www.ncbi.nlm.nih.gov/pubmed/29852043.

65.

•• Cameron D, Piccart-Gebhart MJ, Gelber RD, Procter M, Goldhirsch A, de Azambuja E, et al. 11 years’ follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive early breast cancer: final analysis of the HERceptin Adjuvant (HERA) trial. Lancet (London, England). Elsevier; 2017 Mar 25 [cited 2018 Aug 14];389(10075):1195–205. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28215665. This study provides long term follow up data confirming that 1 year of adjuvant trastuzumab after chemotherapy for patients with HER2-positive early breast cancer significantly improves long-term disease-free survival which confirms our standard of care.

66.

Pivot X, Romieu G, Debled M, Pierga J-Y, Kerbrat P, Bachelot T, et al. 6 months versus 12 months of adjuvant trastuzumab for patients with HER2-positive early breast cancer (PHARE): a randomised phase 3 trial. Lancet Oncol. 2013 Jul [cited 2018 Sep 10];14(8):741–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23764181.CrossRef

67.

PERSEPHONE: 6 versus 12 months (m) of adjuvant trastuzumab in patients (pts) with HER2 positive (+) early breast cancer (EBC): Randomised phase 3 non-inferiority trial with definitive 4-year (yr) disease-free survival (DFS) results. 2018 ASCO Annual Meeting Abstracts [Internet]. [cited 2018 Aug 14]. Available from: http://abstracts.asco.org/214/AbstView_214_217191.html

68.

Tolaney SM, Barry WT, Dang CT, Yardley DA, Moy B, Marcom PK, et al. Adjuvant Paclitaxel and Trastuzumab for node-negative, HER2-positive breast cancer. N Engl J Med. Massachusetts Medical Society; 2015 Jan 8 [cited 2018 Sep 7];372(2):134–41. Available from: http://www.nejm.org/doi/10.1056/NEJMoa1406281 CrossRef

69.

Adjuvant Paclitaxel and Trastuzumab for Node-Negative, HER2-Positive Breast Cancer. N Engl J Med. Massachusetts Medical Society; 2015 Nov 12 [cited 2018 Sep 10];373(20):1989–1989. Available from: http://www.nejm.org/doi/10.1056/NEJMx150037

70.

Rimawi MF, Schiff R, Osborne CK. Targeting HER2 for the treatment of breast cancer. Annu Rev Med [Internet]. Annual Reviews ; 2015 Jan 14 [cited 2018 Aug 9];66(1):111–28. Available from: http://www.annualreviews.org/doi/10.1146/annurev-med-042513-015127 CrossRef

71.

Dall P, Koch T, Göhler T, Selbach J, Ammon A, Eggert J, et al. Trastuzumab without chemotherapy in the adjuvant treatment of breast cancer: subgroup results from a large observational study. BMC Cancer [Internet]. BioMed Central; 2018 [cited 2018 Aug 13];18(1):51. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29310623.

72.

Evaluation of trastuzumab without chemotherapy as a postoperative adjuvant therapy in HER2-positive elderly breast cancer patients: randomized controlled trial (RESPECT). 2018 ASCO Annual Meeting Abstracts [Internet]. [cited 2018 Aug 14]. Available from: http://abstracts.asco.org/214/AbstView_214_214387.html

73.

Rimawi MF, Wiechmann LS, Wang Y-C, Huang C, Migliaccio I, Wu M-F, et al. Reduced dose and intermittent treatment with lapatinib and trastuzumab for potent blockade of the HER pathway in HER2/neu-overexpressing breast tumor xenografts. Clin Cancer Res [Internet]. 2011 Mar 15 [cited 2018 Aug 14];17(6):1351–61. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21138857.CrossRef

74.

Arpino G, Gutierrez C, Weiss H, Rimawi M, Massarweh S, Bharwani L, et al. Treatment of human epidermal growth factor receptor 2-overexpressing breast cancer xenografts with multiagent HER-targeted therapy. J Natl Cancer Inst. 2007 May 2 [cited 2018 Aug 14];99(9):694–705. Available from: https://academic.oup.com/jnci/article-lookup/doi/10.1093/jnci/djk151 CrossRef

75.

• Llombart-Cussac A, Cortés J, Paré L, Galván P, Bermejo B, Martínez N, et al. HER2-enriched subtype as a predictor of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer (PAMELA): an open-label, single-group, multicentre, phase 2 trial. Lancet Oncol. 2017 Apr [cited 2018 Aug 9];18(4):545–54. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28238593. This study provides evidence that the HER2-enriched subtype can identify patients with HER2-positive breast cancer who are likely to benefit from dual HER2 blockade therapies. CrossRef

76.

Rimawi MF, Mayer IA, Forero A, Nanda R, Goetz MP, Rodriguez AA, et al. Multicenter phase II study of neoadjuvant lapatinib and trastuzumab with hormonal therapy and without chemotherapy in patients with human epidermal growth factor receptor 2–overexpressing breast cancer: TBCRC 006. J Clin Oncol [Internet]. 2013 May 10 [cited 2018 Aug 9];31(14):1726–31. Available from: http://ascopubs.org/doi/10.1200/JCO.2012.44.8027 CrossRef

77.

Di Cosimo S, Campbell C, Azim HA, Galli G, Bregni G, Curigliano G, et al. The use of breast imaging for predicting response to neoadjuvant lapatinib, trastuzumab and their combination in HER2-positive breast cancer: Results from Neo-ALTTO. Eur J Cancer [Internet]. 2018 Jan [cited 2018 Sep 7];89:42–8. Available from: http://www.ncbi.nlm.nih.gov/pubmed/29227816.

78.

Connolly RM, Leal JP, Solnes L, Huang CY, Carpenter A, Gaffney K, Abramson V, Carey L, Liu M, Rimawi M, Specht J, Storniolo AM, Valero V, Vaklavas C, Camp M, Miller RS, Wolff AC, Cimino-Mathews A, Wahl RL10 SV. TBCRC026: Phase II clinical trial assessing the correlation of standardized uptake value (SUV) on positron emission tomography (PET/CT) with pathological complete response (pCR) to pertuzumab and trastuzumab in primary operable HER2-positive breast cancer. 2018.

79.

Chemotherapy-free trastuzumab and pertuzumab in HER2-positive breast cancer: FDG-PET response-adapted strategy. - Full Text View - ClinicalTrials.gov. [cited 2018 Aug 14]. Available from: https://clinicaltrials.gov/ct2/show/NCT03161353

80.

HER2-enriched subtype and ERBB2 mRNA as predictors of pathological complete response following trastuzumab and lapatinib without chemotherapy in early-stage HER2-positive breast cancer: a combined analysis of TBCRC006/023 and PAMELA trials. | 2018 ASCO Annual Meeting Abstracts [Internet]. [cited 2018 Aug 14]. Available from: http://abstracts.asco.org/214/AbstView_214_228677.html

81.

Harbeck N, Gluz O, Christgen M, Kates RE, Braun M, Küemmel S, et al. De-escalation strategies in human epidermal growth factor receptor 2 (HER2)–positive early breast cancer (BC): final analysis of the West German Study Group Adjuvant Dynamic Marker-Adjusted Personalized Therapy Trial Optimizing Risk Assessment and Therapy. J Clin Oncol. 2017;35(26):3046–54.CrossRef

82.

Hofmann D, Nitz U, Gluz O, Kates RE, Schinkoethe T, Staib P, et al. WSG ADAPT—adjuvant dynamic marker-adjusted personalized therapy trial optimizing risk assessment and therapy response prediction in early breast cancer: study protocol for a prospective, multi-center, controlled, non-blinded, randomized, investigator in. Trials. 2013 Aug 19 [cited 2018 Aug 27];14(1):261. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23958221.

83.

Stagg J, Loi S, Divisekera U, Ngiow SF, Duret H, Yagita H, et al. Anti-ErbB-2 mAb therapy requires type I and II interferons and synergizes with anti-PD-1 or anti-CD137 mAb therapy. Proc Natl Acad Sci U S A [Internet]. National Academy of Sciences; 2011 Apr 26 [cited 2017 Dec 19];108(17):7142–7. Available from: http://www.ncbi.nlm.nih.gov/pubmed/21482773.

84.

Hendrickx W, Simeone I, Anjum S, Mokrab Y, Bertucci F, Finetti P, et al. Identification of genetic determinants of breast cancer immune phenotypes by integrative genome-scale analysis. Oncoimmunology [Internet]. 2017 Feb 8 [cited 2018 Aug 14];6(2):e1253654. Available from: http://www.ncbi.nlm.nih.gov/pubmed/28344865.CrossRef

85.

Dirix LY, Takacs I, Jerusalem G, Nikolinakos P, Arkenau H-T, Forero-Torres A, et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN Solid Tumor study. Breast Cancer Res Treat. Springer US; [cited 2017 Dec 18];167(3). Available from: http://link.springer.com/10.1007/s10549-017-4537-5

86.

Loi S, Giobbe-Hurder A, Gombos A, Bachelot T, Hui R, Curigliano G, et al. Abstract GS2–06: Phase Ib/II study evaluating safety and efficacy of pembrolizumab and trastuzumab in patients with trastuzumab-resistant HER2-positive metastatic breast cancer: Results from the PANACEA (IBCSG 45–13/BIG 4–13/KEYNOTE-014) study. Cancer Res. American Association for Cancer Research; 2018 Feb 15 [cited 2018 Sep 7];78(4 Supplement):GS2–06-GS2–06. Available from: http://cancerres.aacrjournals.org/lookup/doi/10.1158/1538-7445.SABCS17-GS2-06

Title: Optimizing HER2-Directed Therapy in Early-Stage Breast Cancer
Authors: Evanthia T. Roussos Torres
Roisin M. Connolly
Publication date: 01-12-2018
Publisher: Springer US
Published in: Current Breast Cancer Reports / Issue 4/2018
Print ISSN: 1943-4588
Electronic ISSN: 1943-4596
DOI: https://doi.org/10.1007/s12609-018-0296-5

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

At a glance: The STEP trials

Springer Medicine

Abstract

Purpose of Review

Recent Findings

Summary

Please log in to get access to this content

Other articles of this Issue 4/2018

Novel Agents for the Management of Endocrine Resistant Breast Cancer

Use of Multigene Prognostic Indices to Guide Clinical Decision-Making Regarding Adjuvant Systemic Therapy

Adjuvant HER2-Targeted Therapy Update in Breast Cancer: Escalation and De-escalation of Therapy in 2018

Non-hormonal Chemoprevention

Phased Implementation as a Strategy for Stepwise, Sustainable Improvement in Breast Healthcare in Low-Resource Settings

Bone-Modifying Agents in Early-Stage and Advanced Breast Cancer

Keynote webinar | Spotlight on antibody–drug conjugates in cancer